Match tier
Listed
Presence
Current · Arkansas
Last published
2025
Sources
OpenAlex · ORCID
Refreshed
2026-08-15
Biography and Research Information
Metrics
- h-index: 1
- Publications: 6
- Citations: 5
Selected Publications
-
Cardiac Allograft Immunoprotection in Combined Heart-Liver Transplantation: Mechanisms and Clinical Translation for the Sensitized Candidate (2026)
-
GLP-1 Agonists and Risk of Atrial Fibrillation in Non-Dialysis Chronic Kidney Disease (2026)
-
Hydrocortisone Use for Septic Shock in Patients With CKD (2026)
-
Treatment Challenges in a Complex Presentation of Diabetic Ketoacidosis, Hyperosmolar Hyperglycemic Syndrome and Hypernatremia: A Case Report (2026)
-
Patterns of cause of death among patients with subsequent primary malignancies after cutaneous melanoma: A SEER-based analysis (2000–2022). (2026)
-
Renal safety and clinical outcomes of enfortumab vedotin plus pembrolizumab in urothelial carcinoma patients with chronic kidney disease. (2026)
-
Continued CNS-penetrant TKI therapy with or without local CNS therapy after brain metastasis diagnosis in NSCLC. (2026)
-
Real-world outcomes of systemic therapy sequencing after earlier-generation EGFR TKI failure in NSCLC with brain metastases. (2026)
-
Fungal DNA in Circulation (2025)
Collaboration Network
Top Collaborators
Atulya Aman Khosla
Beaumont Hospital, Royal Oak (US)
4 shared publications
- Real-world outcomes of systemic therapy sequencing after earlier-generation EGFR TKI failure in NSCLC with brain metastases.
- Continued CNS-penetrant TKI therapy with or without local CNS therapy after brain metastasis diagnosis in NSCLC.
- Renal safety and clinical outcomes of enfortumab vedotin plus pembrolizumab in urothelial carcinoma patients with chronic kidney disease.
- Patterns of cause of death among patients with subsequent primary malignancies after cutaneous melanoma: A SEER-based analysis (2000–2022).
M Pustake
Texas Tech University (US)
4 shared publications
- Real-world outcomes of systemic therapy sequencing after earlier-generation EGFR TKI failure in NSCLC with brain metastases.
- Continued CNS-penetrant TKI therapy with or without local CNS therapy after brain metastasis diagnosis in NSCLC.
- Renal safety and clinical outcomes of enfortumab vedotin plus pembrolizumab in urothelial carcinoma patients with chronic kidney disease.
- Patterns of cause of death among patients with subsequent primary malignancies after cutaneous melanoma: A SEER-based analysis (2000–2022).
Mohammad Arfat Ganiyani
Baptist Hospital of Miami (US)
4 shared publications
- Real-world outcomes of systemic therapy sequencing after earlier-generation EGFR TKI failure in NSCLC with brain metastases.
- Continued CNS-penetrant TKI therapy with or without local CNS therapy after brain metastasis diagnosis in NSCLC.
- Renal safety and clinical outcomes of enfortumab vedotin plus pembrolizumab in urothelial carcinoma patients with chronic kidney disease.
- Patterns of cause of death among patients with subsequent primary malignancies after cutaneous melanoma: A SEER-based analysis (2000–2022).
Nitya Batra
Jacksonville College (US)
3 shared publications
- Real-world outcomes of systemic therapy sequencing after earlier-generation EGFR TKI failure in NSCLC with brain metastases.
- Continued CNS-penetrant TKI therapy with or without local CNS therapy after brain metastasis diagnosis in NSCLC.
- Renal safety and clinical outcomes of enfortumab vedotin plus pembrolizumab in urothelial carcinoma patients with chronic kidney disease.
Karan Jatwani
George Washington University Hospital (US)
3 shared publications
- Real-world outcomes of systemic therapy sequencing after earlier-generation EGFR TKI failure in NSCLC with brain metastases.
- Continued CNS-penetrant TKI therapy with or without local CNS therapy after brain metastasis diagnosis in NSCLC.
- Renal safety and clinical outcomes of enfortumab vedotin plus pembrolizumab in urothelial carcinoma patients with chronic kidney disease.
Rohan Garje
Miami Heart Research Institute (US)
3 shared publications
- Real-world outcomes of systemic therapy sequencing after earlier-generation EGFR TKI failure in NSCLC with brain metastases.
- Renal safety and clinical outcomes of enfortumab vedotin plus pembrolizumab in urothelial carcinoma patients with chronic kidney disease.
- Patterns of cause of death among patients with subsequent primary malignancies after cutaneous melanoma: A SEER-based analysis (2000–2022).
Nishank Jain
University of Arkansas for Medical Sciences
2 shared publications
In database
- Fungal DNA in Circulation
- Renal safety and clinical outcomes of enfortumab vedotin plus pembrolizumab in urothelial carcinoma patients with chronic kidney disease.
Yagnapriya Ammakola
2 shared publications
- Real-world outcomes of systemic therapy sequencing after earlier-generation EGFR TKI failure in NSCLC with brain metastases.
- Continued CNS-penetrant TKI therapy with or without local CNS therapy after brain metastasis diagnosis in NSCLC.
Rohit Singh
University of Vermont Medical Center (US)
2 shared publications
- Real-world outcomes of systemic therapy sequencing after earlier-generation EGFR TKI failure in NSCLC with brain metastases.
- Continued CNS-penetrant TKI therapy with or without local CNS therapy after brain metastasis diagnosis in NSCLC.
M. Ahluwalia
Baptist Hospital of Miami (US)
2 shared publications
- Real-world outcomes of systemic therapy sequencing after earlier-generation EGFR TKI failure in NSCLC with brain metastases.
- Continued CNS-penetrant TKI therapy with or without local CNS therapy after brain metastasis diagnosis in NSCLC.
John Arthur
Central Arkansas Veterans Healthcare System
1 shared publication
In database
- Fungal DNA in Circulation
Akshee Batra
Jackson Health System (US)
1 shared publication
- Real-world outcomes of systemic therapy sequencing after earlier-generation EGFR TKI failure in NSCLC with brain metastases.
Kevin Zhu
University of Vermont Medical Center (US)
1 shared publication
- Continued CNS-penetrant TKI therapy with or without local CNS therapy after brain metastasis diagnosis in NSCLC.
Yagnapriya Ammakola
1 shared publication
- Renal safety and clinical outcomes of enfortumab vedotin plus pembrolizumab in urothelial carcinoma patients with chronic kidney disease.
Mohammed Ganiyani
Baptist Hospital of Miami (US)
1 shared publication
- Patterns of cause of death among patients with subsequent primary malignancies after cutaneous melanoma: A SEER-based analysis (2000–2022).